Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571 - PubMed (original) (raw)

. 2001 Nov 1;98(9):2808-16.

doi: 10.1182/blood.v98.9.2808.

Affiliations

• PMID: 11675355
• DOI: 10.1182/blood.v98.9.2808

Free article

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571

N C Wolff et al. Blood. 2001.

Free article

Abstract

The murine bone marrow retroviral transduction and transplantation model of chronic myelogenous leukemia (CML) imperfectly mimics human CML because the murine CML-like disease causes death of all animals from an overwhelming granulocytosis within 3 to 4 weeks. In this report, mice reconstituted with P210(BCR/ABL)-transduced bone marrow cells received posttransplantation therapy with either the tyrosine kinase inhibitor STI571 or placebo. Compared with the rapidly fatal leukemia of placebo-treated animals, 80% of the STI571-treated mice were alive on day 74, with marked improvement in peripheral white blood counts and splenomegaly. There was decreased tyrosine phosphorylation of STAT5, Shc, and Crk-L in leukemic cells from STI571-treated animals, consistent with STI571-mediated inhibition of the Bcr/Abl tyrosine kinase in vivo. In some STI571-treated animals Bcr/Abl messenger RNA and protein expression were markedly increased. In contrast to the polyclonal leukemia of placebo-treated mice, STI571-treated murine CML was generally oligoclonal, suggesting that STI571 eliminated or severely suppressed certain leukemic clones. None of the STI571-treated mice were cured of the CML-like myeloproliferative disorder, however, and STI571-treated murine CML was transplanted to secondary recipients with high efficiency. These results demonstrate the utility of this murine model of CML in the evaluation of novel therapeutic agents against Bcr/Abl-induced leukemias. This improved murine chronic-phase CML model may be a useful tool for the study of STI571 resistance, CML progression, and the anti-CML immune response.

PubMed Disclaimer

Similar articles

• PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
  Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr. Wolff NC, et al. Blood. 2005 May 15;105(10):3995-4003. doi: 10.1182/blood-2004-09-3534. Epub 2005 Jan 18. Blood. 2005. PMID: 15657179 Free PMC article.
• Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
  Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Shi X, et al. Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24. Clin Cancer Res. 2009. PMID: 19240172
• [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
  Nakajima M, Toga W. Nakajima M, et al. Nihon Yakurigaku Zasshi. 2003 Dec;122(6):482-90. doi: 10.1254/fpj.122.482. Nihon Yakurigaku Zasshi. 2003. PMID: 14639002 Review. Japanese.
• STI571 as a targeted therapy for CML.
  O'Dwyer ME, Mauro MJ, Druker BJ. O'Dwyer ME, et al. Cancer Invest. 2003 Jun;21(3):429-38. doi: 10.1081/cnv-120018235. Cancer Invest. 2003. PMID: 12901289 Review.

Cited by

• Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
  Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW. Agarwal A, et al. Blood. 2012 Sep 27;120(13):2658-68. doi: 10.1182/blood-2011-05-355396. Epub 2012 Aug 13. Blood. 2012. PMID: 22889761 Free PMC article.
• Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
  Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. Mohi MG, et al. Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3130-5. doi: 10.1073/pnas.0400063101. Epub 2004 Feb 19. Proc Natl Acad Sci U S A. 2004. PMID: 14976243 Free PMC article.
• Src kinase signaling in leukaemia.
  Li S. Li S. Int J Biochem Cell Biol. 2007;39(7-8):1483-8. doi: 10.1016/j.biocel.2007.01.027. Epub 2007 Feb 9. Int J Biochem Cell Biol. 2007. PMID: 17350876 Free PMC article. Review.
• Evolution of therapies for chronic myelogenous leukemia.
  Santos FP, Kantarjian H, Quintás-Cardama A, Cortes J. Santos FP, et al. Cancer J. 2011 Nov-Dec;17(6):465-76. doi: 10.1097/PPO.0b013e31823dec8d. Cancer J. 2011. PMID: 22157290 Free PMC article. Review.
• Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.
  Williams RT, den Besten W, Sherr CJ. Williams RT, et al. Genes Dev. 2007 Sep 15;21(18):2283-7. doi: 10.1101/gad.1588607. Epub 2007 Aug 30. Genes Dev. 2007. PMID: 17761812 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Miscellaneous

  • NCI CPTAC Assay Portal